Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Synteins-based Therapy
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : $50.0 million
Deal Type : Financing
Flagship’s Abiologics sets sail with $50M for synthetic protein R&D
Details : The proceeds will advance company's platform and develop a diverse pipeline of medicines, Synteins, with an initial focus on oncology and immunology indications.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 23, 2024
Lead Product(s) : Synteins-based Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Flagship Pioneering
Deal Size : $50.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?